TY - ADVS
T1 - Long-Term Survival Update From Secondary Analysis of Stockholm Tamoxifen Trial
AU - Cutter, Noelle L
N1 - By: Noelle Cutter, PhD Posted: Monday, September 13, 2021 Long-term survival of patients with breast cancer receiving endocrine therapy is poorly understood. In a recent study aimed to determine the impact of adjuvant tamoxifen in patients with lymph node-negative, estrogen receptor-positive/ ERBB2-negative breast cancer, Anna Nordenskjöld, MD, PhD, and colleagues from Karolinska Institutet and University Hospital, Stockholm, determined that there was a significant long-term benefit from tamoxifen observed in patients with larger, lower-grade, and progesterone receptor-positive tumors.
PY - 2021/9/13
Y1 - 2021/9/13
N2 - Long-term survival of patients with breast cancer receiving endocrine therapy is poorly understood. In a recent study aimed to determine the impact of adjuvant tamoxifen in patients with lymph node–negative, estrogen receptor–positive/ERBB2-negative breast cancer, Anna Nordenskjöld, MD, PhD, and colleagues from Karolinska Institutet and University Hospital, Stockholm, determined that there was a significant long-term benefit from tamoxifen observed in patients with larger, lower-grade, and progesterone receptor–positive tumors. Their results were published in JAMA Network Open.
AB - Long-term survival of patients with breast cancer receiving endocrine therapy is poorly understood. In a recent study aimed to determine the impact of adjuvant tamoxifen in patients with lymph node–negative, estrogen receptor–positive/ERBB2-negative breast cancer, Anna Nordenskjöld, MD, PhD, and colleagues from Karolinska Institutet and University Hospital, Stockholm, determined that there was a significant long-term benefit from tamoxifen observed in patients with larger, lower-grade, and progesterone receptor–positive tumors. Their results were published in JAMA Network Open.
UR - https://jnccn360.org/breast/news/long-term-survival-update-from-secondary-analysis-of-stockholm-tamoxifen-trial/
M3 - Web publication/site
ER -